COPD: LPS + fMLP PK/PD model – Neutrophil Elastase Targets
Neutrophil Elastase play an important role in the development of chronic obstructive pulmonary disease (COPD), resulting in extensive tissue damage and malfunctioning of the airways.
Intratracheal administration of fMLP degranulates neutrophils in the lung tissue induced by the LPS challenge to release neutrophil elastase into the airways.
Administration of fMLP in a model of LPS results in higher HNE activity, this is reversed by administration of the positive control Sivelestat (human neutrophil elastase inhibitor)
SD rat, C57BL/6J mouse
|LPS + fMLP PK/PD model
|Assessing the efficacy of novel compounds targeted at neutrophil elastase
|HNE activity, BAL differential cell count, and BAL cytokines
Study data generated by Labcorp Huntingdon Pharmacology.